Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/10/2019
SIETES contiene 92826 citas

 
 
 1 a 20 de 86 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Cummings SR, Lui LY, Eastell R, Allen IE. Association between drug treatments for patients with osteoporosis and overall mortality rates: a meta-analysis. JAMA Intern Med 2019:19 de agosto. [Ref.ID 103179]
2.Enlace a cita original Cita con resumen
Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, opportunities, and reality of biosimilar medications. N Engl J Med 2018;378:24 de mayo. [Ref.ID 102636]
3. Cita con resumen
Anónimo. Teriparatide: Shock and loss of consciousness. Japan . WHO Drug Information 2018;32:18. [Ref.ID 102621]
4. Cita con resumen
Anónimo. Diphosphonates: valvulopathies?. Prescrire 2017;37:511-2. [Ref.ID 102010]
6. Cita con resumen
Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie S-A. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 2015;386:1147-55. [Ref.ID 99538]
7. Cita con resumen
Anónimo. Osteoporosis postmenopáusica: un consenso necesario. Infac: Información Farmacoterapéutica de la Comarca 2015;23:27-32. [Ref.ID 99199]
8. Cita con resumen
Anónimo. Lésions de la muqueuse oesophagienne d'origine médicamenteuse. Prescrire 2014;34:905-10. [Ref.ID 98473]
9.Tiene citas relacionadas
Bischoff-Ferrari HA, Meyer O. Comparative effectiveness of pharmacologic treatments to prevent fractures: is this all we need to know?. Ann Intern Med 2014;161:711-23. [Ref.ID 98329]
10.Tiene citas relacionadas Cita con resumen
Crandall CJ, Newberry SJ, Diamant A, Lim Y-W, Gellad WF, Booth MJ, Motala A, Shekelle PG. Comparative effectiveness of pharmacologic treatments to prevent fractures: and updated systematic review. Ann Intern Med 2014;161:711-23. [Ref.ID 98328]
11. Cita con resumen
Anónimo. Drugs for postmenopausal osteoporosis. Med Lett Drugs Ther 2014;56:91-6. [Ref.ID 98234]
12. Cita con resumen
13.Tiene citas relacionadas Cita con resumen
Becker CB. Sclerostin inhibition for osteoporosis - a new approach. N Engl J Med 2014;370:476-7. [Ref.ID 97066]
14.Tiene citas relacionadas Cita con resumen
McClung M, Grauer A, Boonen S, Bolognese MA, Brown JP, Díez-Pérez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014;370:412-20. [Ref.ID 97064]
15.Tiene citas relacionadas Cita con resumen
Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie S-AM, Neer RM, Leder BZ. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 2013;382:50-6. [Ref.ID 95788]
16.Tiene citas relacionadas
Eastell R, Walsh JS. Is it time to combine osteoporosis therapies?. Lancet 2013;382:5-7. [Ref.ID 95783]
17. Cita con resumen
Anónimo. Pour mieux soigner: des médicaments à écarter. Prescrire 2013;33:138-42. [Ref.ID 94882]
18. Cita con resumen
Freemantle N, Cooper C, Díez-Pérez A, Gitlin M, Radcliffe H, Shepherd S, Roux C. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 2013;24:209-17. [Ref.ID 94651]
19. Cita con resumen
Murad MH, Drake MT, Mullan RJ, Mauk KF, Stuart LM, Lane MA, Abu Elnour NO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2012;97:1871-80. [Ref.ID 92114]
20. Cita con resumen
Weiss-Smith S, Deshpande G, Chung S, Gogolak V. The FDA Drug Safety Surveillance Program: adverse event reporting trends. Arch Intern Med 2011;171:592. [Ref.ID 91171]
Seleccionar todas
 
 1 a 20 de 86 siguiente >>